| Budget Amount *help |
¥16,510,000 (Direct Cost: ¥12,700,000、Indirect Cost: ¥3,810,000)
Fiscal Year 2017: ¥4,030,000 (Direct Cost: ¥3,100,000、Indirect Cost: ¥930,000)
Fiscal Year 2016: ¥4,030,000 (Direct Cost: ¥3,100,000、Indirect Cost: ¥930,000)
Fiscal Year 2015: ¥4,030,000 (Direct Cost: ¥3,100,000、Indirect Cost: ¥930,000)
Fiscal Year 2014: ¥4,420,000 (Direct Cost: ¥3,400,000、Indirect Cost: ¥1,020,000)
|
|---|
| Outline of Final Research Achievements |
The purpose of our study is to develop a novel PET imaging agent for early diagnosis of Alzheimer's disease, a severity diagnosis and an effect of treatment judgment. We targeted the acetylcholine transporter(VAChT) which exist in pre-synapse in cholinergic nerve system, which is related to the cognitive impairment of Alzheimer's disease. We newly synthesized (-)-o-[11C]methyl-trans-decalinvesamicol((-)-[11C]OMDV) and o-[77Br]Bromo-trans-decalinvesamicol([77Br]OBDV). (-)-[11C]OMDV and [77Br]OBDV showed a high binding affinity and selectivity for VAChT. In vivo studies demonstrated [11C]OMDV and [77Br]OBDV passage through the blood-brain barrier (BBB) and accumulation in the rat brain. The regional brain distribution of them was accordance with the density distribution of VAChT in brain. These results showed (-)-[11C]OMDV and [77Br]OBDV bound selectively to VAChT in vivo. (-)-[11C]OMDV and [77Br]OBDV was suggested to be useful as a VAChT imaging agent for PET.
|
